EISAI INC. for EISAI INC.
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 21, 2015 | $510,000 | Replaced |
| 2nd Quarter - Amendment | Dec 13, 2016 | $510,000 | Yes |
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Defense DEF
DoD/TRICARE coverage of FDA-approved obesity drugs National Defense Authorization Bill for 2016 (HR 1735/S 1376) Department of Defense Appropriations Bill for 2016 (HR 2685/S 1558)
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CLARK | — |
| STEPHEN D MCMILLAN | — |
| ANGELA STEWART | — |
Copyright/Patent/Trademark CPT
IP issues related to the Trade Promotion Authority and Trans Pacific Partnership HR 9/S 1137 - The Innovation Act/PATENT Act HR 1314/S 995 - Trade Act of 2015/Bipartisan Congressional Trade Priorities and Accountability Act of 2015
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CLARK | — |
| STEPHEN D MCMILLAN | — |
| ANGELA STEWART | — |
Budget/Appropriations BUD
Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of obesity Rx products H Con Res 27 - Establishing the budget for the United States Government for FY 2016 and setting forth appropriate budgetary levels for FYs 2017 through 2025. S Con Res 11 - An original concurrent resolution setting forth the congressional budget for the United States Government for Fiscal Year 2016 and setting for the appropriate budgetary levels for fiscal years 2017 through 2025.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CLARK | — |
| STEPHEN D MCMILLAN | — |
| ANGELA STEWART | — |
Pharmacy PHA
DEA scheduling of controlled substances H.R. 639/S 481 - Improving Regulatory Transparency for New Medical Therapies Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CLARK | — |
| STEPHEN D MCMILLAN | — |
| ANGELA STEWART | — |
Medicare/Medicaid MMM
Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of FDA-approved obesity drugs. H.R. 2 - Medicare Access and CHIP Reauthorization Act of 2015 S. 810 - SGR Repeal and Medicare Provider Payment Modernization Act of 2015 H.R. 2404/S 1509 - Treat and Reduce Obesity Act of 2015
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CLARK | — |
| STEPHEN D MCMILLAN | — |
| ANGELA STEWART | — |
Health Issues HCR
Implementation issues related to the Pharmaceutical Quality, Security and Accountability Act (P.L. 113-54) Regulatory and legislative health care issues, including the 340B program HR6 - 21st Century Cures Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CLARK | — |
| STEPHEN D MCMILLAN | — |
| ANGELA STEWART | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.